Amedeo Smart

Free Medical Literature Service

 

Amedeo

Antiretroviral Therapy
  Free Subscription

Articles published in
AIDS
    September 2025
  1. DIETERICH DT, Brunet L, Hsu RK, Mounzer K, et al
    Tenofovir interruption among people with HIV and HBV: HBV monitoring and risk of HBV reactivation and hepatitis flare.
    AIDS. 2025 Sep 19. doi: 10.1097/QAD.0000000000004353.
    >> Share

  2. SOULIE C, Balde A, Fofana D, Charpentier C, et al
    No evidence of an effect of the M184I/V on the doravirine/lamivudine/tenofovir switch efficacy in people living with HIV.
    AIDS. 2025 Sep 8. doi: 10.1097/QAD.0000000000004339.
    >> Share

  3. PATEL N, Dulion B, Lazcano I, Shi Q, et al
    Antiretroviral-specific associations between bone hormonal changes and treatment induced weight gain.
    AIDS. 2025 Sep 4. doi: 10.1097/QAD.0000000000004330.
    >> Share

  4. ANTWI S, Yang H, Enimil A, Martyn-Dickens C, et al
    Tenofovir diphosphate concentrations in dried blood spots predict future HIV suppression but not virologic failure in adolescents with HIV.
    AIDS. 2025;39:1668-1671.
    >> Share

    August 2025
  5. KAMPHUIS AEM, Kiezebrink T, Waalewijn H, Bamford A, et al
    Pharmacokinetics of lopinavir/ritonavir in second-line treatment of children living with HIV in the CHAPAS-4 trial.
    AIDS. 2025 Aug 26. doi: 10.1097/QAD.0000000000004328.
    >> Share

  6. CANIGLIA EC, Zash R, Diseko M, Mabuta J, et al
    Target trials of pre-conception switch from Nevirapine- or Efavirenz-based ART to dolutegravir-based ART on adverse birth and maternal outcomes.
    AIDS. 2025 Aug 13. doi: 10.1097/QAD.0000000000004321.
    >> Share

  7. CALCAGNO A, Carola L, Barbara R, Marco M, et al
    Full reservoirs and poor adherence: two cases of symptomatic HIV cerebrospinal fluid escape with tenofovir alafenamide/emtricitabine/bictegravir.
    AIDS. 2025 Aug 8. doi: 10.1097/QAD.0000000000004320.
    >> Share

    July 2025
  8. STEFFEN HM, Viola E, Thawani A, Kachere LG, et al
    Blood pressure, weight change and incident hypertension after switching to dolutegravir in treatment-experienced people living with HIV.
    AIDS. 2025 Jul 24. doi: 10.1097/QAD.0000000000004309.
    >> Share

  9. DARJI D, Norris S, Ohuma EO, Hemelaar J, et al
    Foetal growth in pregnant women with HIV: longitudinal analysis of serial ultrasound measurements in South Africa.
    AIDS. 2025 Jul 8. doi: 10.1097/QAD.0000000000004294.
    >> Share

    June 2025
  10. MATA MARIN JA, Rodriguez Evaristo MS, Cano Diaz AL, Salinas Velazquez GE, et al
    Incidence of Metabolic syndrome in people with HIV without experienCe to antiretroviral Therapy who start doLutegravir based-regimen compared with bictegrAvir based-regimeN after 48 weeks (MICTLAN trial).
    AIDS. 2025 Jun 5. doi: 10.1097/QAD.0000000000004259.
    >> Share

    May 2025
  11. DING Y, Li J, Gao C, Xing L, et al
    Machine learning algorithms to predict the risk of hyperlipidemia in people living with HIV after starting HAART for 6 months.
    AIDS. 2025 May 21. doi: 10.1097/QAD.0000000000004244.
    >> Share

  12. MEZZADRI L, Soria AG, Ranzani A, Malandrin S, et al
    Hepatitis B core antibody positivity is not associated with risk of transaminase elevation following switch to dual antiretroviral therapy.
    AIDS. 2025 May 3. doi: 10.1097/QAD.0000000000004227.
    >> Share

  13. CLEMENTE T, Bellomo M, Raccagni AR, Lolatto R, et al
    Sexually transmitted infections in men who have sex with men with tenofovir/emtricitabine- or cabotegravir-resistant HIV.
    AIDS. 2025 May 3. doi: 10.1097/QAD.0000000000004225.
    >> Share

  14. ABDALLA S, Compagnucci A, Bamford A, Chan MK, et al
    Assessment of the steady-state drug-drug interactions between dolutegravir and ritonavir-boosted darunavir in adolescents.
    AIDS. 2025 May 3. doi: 10.1097/QAD.0000000000004223.
    >> Share

    April 2025
  15. HEJBLUM G, Daher S, Moulaire P, Amat K, et al
    Cost-effectiveness of a 4 days-a-week triple therapy in persons living with HIV: an ancillary study of the QUATUOR trial.
    AIDS. 2025 Apr 22. doi: 10.1097/QAD.0000000000004215.
    >> Share

  16. WANG L, Li SM, Li X, Wu HS, et al
    The transmembrane nucleoporin Nup210 weakens HIV-1 infection via modulating late events of viral nuclear import.
    AIDS. 2025 Apr 9. doi: 10.1097/QAD.0000000000004206.
    >> Share

  17. MOLLAN KR, Pence BW, Westreich D, Bula A, et al
    Effectiveness of levonorgestrel implant and depot medroxyprogesterone acetate injectable for women living with HIV on efavirenz: a prospective cohort study.
    AIDS. 2025 Apr 3. doi: 10.1097/QAD.0000000000004201.
    >> Share

  18. RIOS-VAZQUEZ V, Vos WAJW, Blaauw MJT, Van Eekeren LE, et al
    Dolutegravir plus lamivudine downregulates cellular stress responses versus three-drug HIV Regimens.
    AIDS. 2025 Apr 1. doi: 10.1097/QAD.0000000000004198.
    >> Share

    March 2025
  19. MOYLE G, Gruber J, Dunbar M, Radtchenko J, et al
    Outcomes in people with HIV who resume or switch to bictegravir/emtricitabine/tenofovir alafenamide following a treatment interruption.
    AIDS. 2025 Mar 4. doi: 10.1097/QAD.0000000000004171.
    >> Share

    February 2025
  20. VAN PAASSEN PM, Boyd AC, Pasternak AO, Maurer I, et al
    Soluble CD14 and IL-12p70 on early ART predict HIV load setpoint after treatment interruption.
    AIDS. 2025 Feb 14. doi: 10.1097/QAD.0000000000004159.
    >> Share

  21. SHEIRA LA, Kwena ZA, Ayieko B, Charlebois ED, et al
    The effect of a social network-based intervention on adherence to HIV pre-exposure prophylaxis and HIV viral suppression among Kenyan fishermen.
    AIDS. 2025 Feb 13. doi: 10.1097/QAD.0000000000004157.
    >> Share

  22. RAMI A, Pozniak AL, Assoumou L, Movahedi R, et al
    Use of doravirine-based regimens in clinical practice in Europe: a real-life retrospective observational study.
    AIDS. 2025 Feb 12. doi: 10.1097/QAD.0000000000004151.
    >> Share

  23. BALDIN G, Salvo PF, Passerotto RA, Iannone V, et al
    'With age comes wisdom': effectiveness and tolerability of dolutegravir + lamivudine in virologically-suppressed people with HIV.
    AIDS. 2025 Feb 12. doi: 10.1097/QAD.0000000000004153.
    >> Share

  24. MATOVU KIWEEWA F, Stranix-Chibanda L, Yende-Zuma N, Dadabhai S, et al
    Bone mineral density changes in breastfeeding women living with HIV on antiretroviral therapy in Eastern and Southern Africa.
    AIDS. 2025 Feb 7. doi: 10.1097/QAD.0000000000004148.
    >> Share

  25. JEENA L, Ferrand RA, Simms V, Kahari C, et al
    Reduced peri-pubertal bone density accrual among Zimbabwean males living with HIV: a longitudinal study.
    AIDS. 2025 Feb 5. doi: 10.1097/QAD.0000000000004134.
    >> Share

    January 2025
  26. SPENCER M, Pieri C, Hamzah L, Popoola J, et al
    Antiretroviral therapy in people with HIV and end-stage kidney disease.
    AIDS. 2025 Jan 27. doi: 10.1097/QAD.0000000000004128.
    >> Share

  27. HANTTU AM, Muniandy M, van der Kolk BW, Lindgren H, et al
    Adipose tissue transcriptome in patients switching efavirenz or a protease inhibitor to raltegravir compared to people without HIV.
    AIDS. 2025 Jan 27. doi: 10.1097/QAD.0000000000004131.
    >> Share

  28. DOLLFUS C, Chenadec JL, Reliquet V, Alby-Laurent F, et al
    Outcomes and challenges in adolescents living with HIV in France: a nationwide cohort study over 35 years (1985-2020).
    AIDS. 2025 Jan 13. doi: 10.1097/QAD.0000000000004121.
    >> Share

  29. CASSIDY AR, Mayondi G, Williams PL, Moabi K, et al
    Neurodevelopmental outcomes in children exposed in utero to dolutegravir- or efavirenz-based ART.
    AIDS. 2025 Jan 6. doi: 10.1097/QAD.0000000000004111.
    >> Share

  30. VANPOUILLE C, Wells A, DeGruttola V, Lynch M, et al
    Cytokine trajectory over time in men and women with HIV on long-term antiretroviral therapy.
    AIDS. 2025;39:1-10.
    >> Share

    December 2024
  31. MATTHEWS LT, Bruxvoort KJ, Jaggernath M, Kriel Y, et al
    Use of tenofovir-based PrEP among pregnant women in South Africa.
    AIDS. 2024 Dec 17. doi: 10.1097/QAD.0000000000004090.
    >> Share

  32. WEISSER M, Mapesi H, Vanobberghen F, Okuma J, et al
    Body weight changes in people living with HIV starting dolutegravir versus efavirenz-based regimens in a large cohort in rural Tanzania.
    AIDS. 2024 Dec 4. doi: 10.1097/QAD.0000000000004085.
    >> Share

    October 2024
  33. ENI-OLUTU A, Mackie NE, Glenn J, Bailey A, et al
    Emerging integrase resistance in an international perinatal virtual clinic.
    AIDS. 2024 Oct 28. doi: 10.1097/QAD.0000000000004048.
    >> Share

  34. VERGORI A, Del Duca G, Lorenzini P, Brita AC, et al
    Impact of switching from EFV/F/TDF to B/F/TAF on psychiatric symptoms and neurocognition.
    AIDS. 2024 Oct 25. doi: 10.1097/QAD.0000000000004043.
    >> Share

  35. DUONG KNC, Schmutz HW, Ben-Umeh KC, Duru EE, et al
    Real-world clinical and economic outcomes from rapid start antiretroviral therapy in HIV: systematic review and meta-analysis.
    AIDS. 2024 Oct 25. doi: 10.1097/QAD.0000000000004046.
    >> Share

  36. OLIVERO R, Williams PL, Sawyer G, Yee LM, et al
    Birth outcomes following bictegravir exposure during pregnancy.
    AIDS. 2024 Oct 15. doi: 10.1097/QAD.0000000000004041.
    >> Share

  37. HEFFRON R, Muwonge TR, Thomas KK, Zewdie K, et al
    Bone density changes in young women in Uganda using tenofovir-based HIV pre-exposure prophylaxis and depot medroxyprogesterone acetate contraception.
    AIDS. 2024 Oct 9. doi: 10.1097/QAD.0000000000004029.
    >> Share

  38. HEY M, Thompson L, Portwood C, Sexton H, et al
    Adverse perinatal outcomes associated with different classes of antiretroviral drugs in pregnant women living with HIV: a systematic review and meta-analysis.
    AIDS. 2024 Oct 8. doi: 10.1097/QAD.0000000000004032.
    >> Share

    September 2024
  39. OVERTON ET, Kantor A, Fitch KV, Mosepele M, et al
    Proteinuria and albuminuria among a global primary CVD prevention cohort of PWH: prevalence and associated factors.
    AIDS. 2024 Sep 16. doi: 10.1097/QAD.0000000000004016.
    >> Share

  40. KUNIHOLM MH, Murenzi G, Shumbusho F, Brazier E, et al
    Association of cardiovascular disease risk with liver steatosis and fibrosis in people living with hiv in low- and middle-income countries.
    AIDS. 2024 Sep 12. doi: 10.1097/QAD.0000000000004012.
    >> Share

  41. ZANIEWSKI E, Skrivankova VW, Brazier E, Avihingsanon A, et al
    Transition to dolutegravir-based ART in 35 low- and middle-income countries: a global survey of HIV care clinics.
    AIDS. 2024 Sep 5. doi: 10.1097/QAD.0000000000004007.
    >> Share

    August 2024
  42. ZEWDIE K, Muwonge T, Ssebuliba T, Bambia F, et al
    A point-of-care tenofovir urine test improves accuracy of self-reported PrEP adherence and increases condomless sex reporting among young women.
    AIDS. 2024 Aug 2. doi: 10.1097/QAD.0000000000003988.
    >> Share


  43. Initial antiretroviral therapy regimen and risk of heart failure: Erratum.
    AIDS. 2024;38:1608.
    >> Share

  44. HURCHUND R, Sibiya SE, Owaga BO, Owira PMO, et al
    Tenofovir alafenamide compared to tenofovir disoproxil fumarate, induces dysglycemia, and dyslipidemia in Wistar rats.
    AIDS. 2024 Aug 1. doi: 10.1097/QAD.0000000000003987.
    >> Share

  45. DONCHEVA R, Behr A, Petitpain N, Massy N, et al
    Atazanavir-induced lithiasis evidenced several years after drug discontinuation.
    AIDS. 2024;38:1604-1605.
    >> Share

    July 2024
  46. CAMPBELL L, Barbini B, Cromarty B, Hamzah L, et al
    Safety of tenofovir alafenamide in people with HIV who experienced proximal renal tubulopathy on tenofovir disoproxil.
    AIDS. 2024;38:1442-1445.
    >> Share

  47. JOHNSON AT, Ntloedibe T, Mendez Reyes JE, Matshaba MS, et al
    Impact of efavirenz on hormone-positive breast cancer survival in women living with HIV.
    AIDS. 2024;38:1439-1442.
    >> Share

  48. HILL AM, Elbirt D
    Should we continue to use tenofovir disoproxil fumarate/lamivudine/dolutegravir for treatment of pregnant women? Interpreting the PROMISE trial.
    AIDS. 2024;38:1430-1431.
    >> Share

  49. KARABAY O
    Concerns and clarifications regarding the article 'Virological, weight, and drug resistance outcomes among patients initiating a dolutegravir-based first line ART regimen in Zimbabwe'.
    AIDS. 2024;38:1273.
    >> Share

  50. LEROY P, Diamantis S, Sellier PO, Hamet G, et al
    Prescriptions of generic antiretroviral drugs in three healthcare centers in the Paris area, France.
    AIDS. 2024;38:1269-1272.
    >> Share

  51. WINSLOW DL
    Is early initiation of antiretroviral therapy important?
    AIDS. 2024;38:1263-1264.
    >> Share

    June 2024
  52. MARTINSON T, Montoya R, Moreira C, Kuncze K, et al
    Point-of-care urine tenofovir test predicts future HIV pre-exposure prophylaxis discontinuation among young users.
    AIDS. 2024 Jun 21. doi: 10.1097/QAD.0000000000003962.
    >> Share

  53. ROSE PC, Davies C, Cotton MF, Otwombe K, et al
    Longitudinal controlled attenuation parameter and liver stiffness in children with and without perinatal HIV infection in South Africa.
    AIDS. 2024 Jun 21. doi: 10.1097/QAD.0000000000003964.
    >> Share

  54. SODEKE O, Milligan K, Ezeuko I, Oladipo A, et al
    Longitudinal viral load outcomes of adults with HIV after detectable viremia on tenofovir, lamivudine, and dolutegravir.
    AIDS. 2024 Jun 13. doi: 10.1097/QAD.0000000000003956.
    >> Share

  55. FUNG K, Hernandez-Diaz S, Zash R, Chadwick EG, et al
    First-trimester exposure to newer antiretroviral agents and congenital anomalies in a U.S. cohort.
    AIDS. 2024 Jun 12. doi: 10.1097/QAD.0000000000003955.
    >> Share

  56. DRECHSLER H, Ayers C, Oboho I, Enwerem N, et al
    Choice of antiretroviral therapy has low impact on weight gain.
    AIDS. 2024 Jun 3. doi: 10.1097/QAD.0000000000003950.
    >> Share

    May 2024
  57. MCCABE L, Burns JE, Latifoltojar A, Post FA, et al
    MAVMET trial: maraviroc and/or metformin for metabolic dysfunction-associated fatty liver disease(MAFLD) in adults with suppressed HIV.
    AIDS. 2024 May 31. doi: 10.1097/QAD.0000000000003947.
    >> Share

  58. MATTHEWS LT, Jaggernath M, Kriel Y, Smith PM, et al
    Oral PrEP uptake, adherence, and persistence during periconception periods among women in South Africa: an intervention study.
    AIDS. 2024 May 15. doi: 10.1097/QAD.0000000000003925.
    >> Share

  59. SALTO JN, Volkow P, Herrera-Goepfert R, Lopez-Garcia AI, et al
    Unmasked Kaposi and sarcoidosis immune reconstitution inflammatory syndrome in a patient with AIDS.
    AIDS. 2024;38:933-934.
    >> Share

    March 2024
  60. WIJSTMA ES, Jongen VW, Boyd A, van den Elshout M, et al
    Concordance between daily diary reported PrEP intake and intraerythrocytic tenofovir diphosphate (TFV-DP) in the Amsterdam PrEP demonstration project.
    AIDS. 2024 Mar 21. doi: 10.1097/QAD.0000000000003889.
    >> Share

  61. MIGISHA R, Chen G, Muyindike WR, Aung TN, et al
    Regional variation in weight change after the transition to dolutegravir: a prospective cohort study in Uganda and South Africa.
    AIDS. 2024 Mar 20. doi: 10.1097/QAD.0000000000003888.
    >> Share

  62. DICKSON S, James K
    Trends in HIV preexposure prophylaxis utilization and spending among individuals with commercial insurance.
    AIDS. 2024;38:610-612.
    >> Share

  63. DADABHAI S, Chou VB, Pinilla M, Chinula L, et al
    Effects of preterm birth, maternal ART and breastfeeding on 24-month infant HIV-free survival in a randomized trial.
    AIDS. 2024 Mar 4. doi: 10.1097/QAD.0000000000003878.
    >> Share

    February 2024
  64. SHIVAKOTI R, Giganti MJ, Lederman MM, Ketchum R, et al
    Systemic inflammation in pregnant women with HIV: relationship with HIV treatment regimen and preterm delivery.
    AIDS. 2024 Feb 26. doi: 10.1097/QAD.0000000000003877.
    >> Share

  65. ORKIN C, Antinori A, Rockstroh JK, Moreno-Guillen S, et al
    Switch to bictegravir/emtricitabine/tenofovir alafenamide from dolutegravir-based therapy: 96-week pooled analysis.
    AIDS. 2024 Feb 12. doi: 10.1097/QAD.0000000000003865.
    >> Share

    January 2024
  66. VAN DER WEKKEN-PAS L, Nassiwa S, Malaba T, Lamorde M, et al
    Comparison of dolutegravir- and efavirenz on depression, anxiety and sleep disorders in pregnant and postpartum women living with HIV; a DolPHIN2 substudy.
    AIDS. 2024 Jan 26. doi: 10.1097/QAD.0000000000003852.
    >> Share

  67. CATTANEO D, Pagano S, Colombo ML, Giacomelli A, et al
    Different effects of the companion antiretroviral drugs on dolutegravir trough concentrations: a focus on novel dual regimens.
    AIDS. 2024 Jan 16. doi: 10.1097/QAD.0000000000003843.
    >> Share

    December 2023
  68. THORNHILL JP, Fox J, Martin GE, Hall R, et al
    Rapid antiretroviral therapy in primary HIV-1 infection enhances immune recovery.
    AIDS. 2023 Dec 21. doi: 10.1097/QAD.0000000000003825.
    >> Share

  69. DORWARD J, Govender K, Moodley P, Lessells R, et al
    Urine tenofovir and dried blood spot tenofovir diphosphate concentrations and viraemia in people taking efavirenz and dolutegravir based antiretroviral therapy.
    AIDS. 2023 Dec 19. doi: 10.1097/QAD.0000000000003818.
    >> Share

  70. MOORE AEB, Burns JE, Sally D, Milinkovic A, et al
    Bone turnover change after randomised switch from tenofovir disoproxil to tenofovir alafenamide fumarate in men with HIV.
    AIDS. 2023 Dec 7. doi: 10.1097/QAD.0000000000003811.
    >> Share

    November 2023
  71. CHERKOS AS, Cranmer LM, Njuguna I, LaCourse SM, et al
    Effect of TB-HIV co-treatment on clinical and growth outcomes among hospitalized children newly initiating antiretroviral therapy.
    AIDS. 2023 Nov 28. doi: 10.1097/QAD.0000000000003797.
    >> Share

  72. HOLDEN CJ, Lampe FC, Burns FM, Chaloner C, et al
    Association of age at ART initiation with CD4:CD8 ratio recovery among virally suppressed people living with HIV, 2001-2019.
    AIDS. 2023 Nov 28. doi: 10.1097/QAD.0000000000003801.
    >> Share

  73. GREGSON CL, Rehman AM, Rukuni R, Mukwasi-Kahari C, et al
    Perinatal HIV infection is associated with deficits in muscle function in children and adolescents: a cross-sectional study in Zimbabwe.
    AIDS. 2023 Nov 22. doi: 10.1097/QAD.0000000000003795.
    >> Share

  74. WILLIAMS PL, Karalius B, Patel K, Aschengrau A, et al
    Fetal growth assessed via ultrasound in relation to maternal HIV infection status and antiretroviral regimens.
    AIDS. 2023 Nov 22. doi: 10.1097/QAD.0000000000003796.
    >> Share

  75. CHAWKI S, Goldwirt L, Mouhebb ME, Gabassi A, et al
    Ex vivo rectal tissue infection with HIV-1 to assess time to protection following oral PrEP with TDF/FTC (a sub-study of the ANRS PREVENIR study).
    AIDS. 2023 Nov 16. doi: 10.1097/QAD.0000000000003789.
    >> Share

  76. LANTZ AM, Cottrell ML, Corbett AH, Chinula L, et al
    Vaginal microbiome, antiretroviral concentrations, and HIV genital shedding in the setting of hormonal contraception initiation in Malawi.
    AIDS. 2023;37:2185-2190.
    >> Share

  77. FILIP I
    The steep cost of HIV treatment interruptions.
    AIDS. 2023;37:N17.
    >> Share

  78. SILVERBERG MJ, Pimentel N, Leyden WA, Leong TK, et al
    Initial antiretroviral therapy regimen and risk of heart failure.
    AIDS. 2023 Nov 14. doi: 10.1097/QAD.0000000000003786.
    >> Share

  79. ZHANG H, Hindman JT, Lin L, Davis M, et al
    A study of the pharmacokinetics, safety, and efficacy of bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed pregnant women with HIV.
    AIDS. 2023 Nov 8. doi: 10.1097/QAD.0000000000003783.
    >> Share

  80. FRANCOIS K, Van Onacker JD, Jordan MR, Journel I, et al
    First case report of a perinatally HIV-infected infant with HIV resistance to dolutegravir associated with tenofovir/lamivudine/dolutegravir use in mothers.
    AIDS. 2023;37:2097-2099.
    >> Share

  81. BREW BJ, Clifford DB
    Antiretroviral therapy intensification for HIV-associated neurocognitive disorder?
    AIDS. 2023;37:2095-2096.
    >> Share

    October 2023
  82. LARTEY M, Ganu VJ, Tachi K, Yang H, et al
    Association of tenofovir diphosphate and lamivudine triphosphate concentrations with HIV and HBV viral suppression.
    AIDS. 2023 Oct 20. doi: 10.1097/QAD.0000000000003764.
    >> Share

  83. WANG Y, Wu G, Wen Z, Lei H, et al
    HAART-related effects on morphological connectivity in HIV: an individual-level morphological brain network study.
    AIDS. 2023 Oct 20. doi: 10.1097/QAD.0000000000003759.
    >> Share

  84. BHATTACHARYA D, Guo R, Tseng CH, Emel L, et al
    Hepatitis B virus clinical and virologic characteristics in an HIV perinatal transmission study in sub-saharan Africa, HPTN 046- a post-hoc analysis.
    AIDS. 2023 Oct 18. doi: 10.1097/QAD.0000000000003752.
    >> Share

  85. MPEBE GGA, Phinius BB, Mutenga S, Baruti K, et al
    Hepatitis B surface antigen loss in chronic hepatitis B virus and HIV-1 Co-Infections individuals in Botswana.
    AIDS. 2023 Oct 16. doi: 10.1097/QAD.0000000000003753.
    >> Share

    September 2023
  86. PARRA-RODRIGUEZ L, O'halloran J, Wang Y, Jin W, et al
    Common antiretroviral combinations are associated with somatic depressive symptoms in women with HIV.
    AIDS. 2023 Sep 29. doi: 10.1097/QAD.0000000000003730.
    >> Share

  87. DAVEY DLJ, Nyemba DC, Mvududu R, Mashele N, et al
    Pregnancy outcomes following self-reported and objective-measured exposure to oral preexposure prophylaxis in South Africa: an observational cohort study.
    AIDS. 2023 Sep 18. doi: 10.1097/QAD.0000000000003729.
    >> Share

  88. MUSTANSKI B, Ryan DT, Spinelli MA, Gandhi M, et al
    Urine point-Of-care tenofovir test demonstrates strong predictive clinical and research utility.
    AIDS. 2023 Sep 6. doi: 10.1097/QAD.0000000000003710.
    >> Share

  89. CHEN RQ, Zino L, Geerlings S, Colbers A, et al
    Exposure to doravirine, lamivudine, tenofovir, and raltegravir in a patient with HIV after a Roux-en-Y gastric bypass.
    AIDS. 2023;37:1769-1771.
    >> Share

    August 2023
  90. PERAZZOLO S, Stephen Z, Eguchi M, Xu X, et al
    A novel formulation enabled transformation of 3 HIV drugs tenofovir-lamivudine-dolutegravir (TLD) from short-acting to long-acting all-in-one injectable.
    AIDS. 2023 Aug 25. doi: 10.1097/QAD.0000000000003706.
    >> Share

  91. BENGTSON AM, Madlala H, Matjila MJ, Levitt N, et al
    Associations of HIV and antiretroviral therapy with gestational diabetes: findings from a prospective cohort in South Africa.
    AIDS. 2023 Aug 3. doi: 10.1097/QAD.0000000000003678.
    >> Share

    July 2023
  92. VERBURGH ML, van der Valk M, Rijnders BJA, Reiss P, et al
    No association between use of tenofovir disoproxil fumarate, etravirine, or integrase-strand transfer inhibitors and acquisition or severe outcomes of SARS-CoV-2 infection in people with HIV in the Netherlands.
    AIDS. 2023;37:1481-1486.
    >> Share

  93. PALICH R, Hentzien M, Hocqueloux L, Duvivier C, et al
    Country of birth is associated with discrepancies in the prescription of two-drug regimens in successfully treated people living with HIV in France.
    AIDS. 2023 Jul 14. doi: 10.1097/QAD.0000000000003657.
    >> Share

  94. VERBURGH ML, Wit FWNM, Boyd A, Reiss P, et al
    No evidence of rapid reversibility of tenofovir alafenamide and/or integrase strand transfer inhibitor-associated weight gain.
    AIDS. 2023 Jul 11. doi: 10.1097/QAD.0000000000003654.
    >> Share

  95. SHIKUMA CM, Wojna V, De Gruttola V, Siriwardhana C, et al
    Impact of ART intensification with CCR5 antagonist maraviroc on HIV-associated neurocognitive impairment.
    AIDS. 2023 Jul 7. doi: 10.1097/QAD.0000000000003650.
    >> Share

  96. HAZRA A, Landovitz RJ, Marzinke MA, Quinby C, et al
    Breakthrough HIV-1 infection in setting of cabotegravir for HIV pre-exposure prophylaxis.
    AIDS. 2023 Jul 4. doi: 10.1097/QAD.0000000000003644.
    >> Share

  97. DIETRICH DK, Laidlaw E, Hammoud DA, Pau AK, et al
    Dramatic Improvement of MRI Abnormalities of HIV Encephalopathy after Suppressive Antiretroviral Therapy.
    AIDS. 2023;37:1339-1340.
    >> Share

    June 2023
  98. PINTYE J, Kinuthia J, Abuna F, Anderson PL, et al
    PrEP initiation, persistence, and adherence during pregnancy through the postpartum period: a prospective analysis in Kenya.
    AIDS. 2023 Jun 7. doi: 10.1097/QAD.0000000000003617.
    >> Share

  99. SMITH C, Silveira L, Crotteau M, Garth K, et al
    Modern antiretroviral regimens in pregnant women: virologic outcomes and durability.
    AIDS. 2023 Jun 7. doi: 10.1097/QAD.0000000000003616.
    >> Share

  100. RAMETSE CL, Webb EL, Herrera C, Alinde B, et al
    A randomized clinical trial of on-demand oral pre-exposure prophylaxis does not modulate lymphoid/myeloid HIV target cell density in the foreskin.
    AIDS. 2023 Jun 7. doi: 10.1097/QAD.0000000000003619.
    >> Share

  101. BARTHOLD D, Saldarriaga EM, Brah AT, Hauber B, et al
    Preference for daily oral pills over long-acting antiretroviral therapy options among people with HIV.
    AIDS. 2023 Jun 7. doi: 10.1097/QAD.0000000000003620.
    >> Share

  102. WARNER NC, Shishido A, Fulco PP, Sastry S, et al
    Immune reconstitution inflammatory syndrome due to monkeypox in two patients with AIDS.
    AIDS. 2023;37:1187-1188.
    >> Share

  103. ZACCARELLI M, Niyongabo B, Conway B
    Point-of-care urine tenofovir testing: making a good thing better.
    AIDS. 2023;37:1159-1160.
    >> Share

    May 2023
  104. KUHN L, Wang T, Li F, Strehlau R, et al
    Microbiota in the oral cavity of school-age children living with HIV who started antiretroviral therapy at young ages in South Africa.
    AIDS. 2023 May 12. doi: 10.1097/QAD.0000000000003599.
    >> Share

  105. AUGELLO M, Bono V, Rovito R, Tincati C, et al
    Six-month immune responses to mRNA-1273 Vaccine in cART-treated late presenter people living with HIV according to previous SARS-CoV-2 Infection.
    AIDS. 2023 May 5. doi: 10.1097/QAD.0000000000003585.
    >> Share


  106. Real world use of dolutegravir two drug regimens: Erratum.
    AIDS. 2023;37:1019.
    >> Share

  107. GUARALDI G, Milic J
    Comparing implications of cardiovascular risk of abacavir and integrase inhibitors: why scientific community is confused and timid?
    AIDS. 2023;37:1005-1008.
    >> Share

    April 2023
  108. MARTYN-DICKENS C, Ojewale O, Sly-Moore E, Dompreh A, et al
    Pharmacokinetics and pharmacodynamics of adult dolutegravir tablets in treatment-experienced children with HIV weighing at least 20 kg.
    AIDS. 2023 Apr 14. doi: 10.1097/QAD.0000000000003576.
    >> Share


  109. Effect of antiretroviral therapy care interruptions on mortality in children living with HIV: Erratum.
    AIDS. 2023;37:859.
    >> Share

    March 2023
  110. STERMAN FL, Lalezari JP, Kowalczyk UM, Main DW, et al
    Bictegravir/Emtricitabine/Tenofovir Alafenamide Plus Doravirine in Highly Treatment-Experienced Men With Multidrug-Resistant HIV.
    AIDS. 2023 Mar 6. doi: 10.1097/QAD.0000000000003513.
    >> Share

  111. SHEN M, Xiao Y, Rong L, Zhuang G, et al
    The impact of attrition on the transmission of HIV and drug resistance: A mathematical modelling study.
    AIDS. 2023 Mar 6. doi: 10.1097/QAD.0000000000003528.
    >> Share

  112. FICHTENBAUM CJ, Mallon P
    Are we ready to RESPOND that the question of abacavir's role in cardiovascular disease events is settled?
    AIDS. 2023;37:541-543.
    >> Share

  113. PATTEN GE, Euvrard J, Anderegg N, Boulle A, et al
    Advanced HIV disease and engagement in care among patients on antiretroviral therapy in South Africa: results from a multi-state model.
    AIDS. 2023;37:513-522.
    >> Share

  114. PORTWOOD C, Sexton H, Kumarendran M, Brandon Z, et al
    Perinatal outcomes associated with combination antiretroviral therapy compared with monotherapy.
    AIDS. 2023;37:489-501.
    >> Share

  115. MONDESERT E, Reynes J, Makinson A, Bargnoux AS, et al
    Cystatin C in addition to creatinine for better assessment of glomerular renal function decline in people with HIV receiving antiretroviral therapy.
    AIDS. 2023;37:447-454.
    >> Share

  116. CASTILLO-ROZAS G, Lopez MN, Soto-Rifo R, Vidal R, et al
    Enteropathy and gut dysbiosis as obstacles to achieve immune recovery in undetectable people with HIV: a clinical view of evidence, successes, and projections.
    AIDS. 2023;37:367-378.
    >> Share

    February 2023
  117. MCCLUSKEY SM, Govender K, Adamson J, Gandhi M, et al
    Point-of-care urine tenofovir testing to predict HIV drug resistance among individuals with virologic failure.
    AIDS. 2023 Feb 17. doi: 10.1097/QAD.0000000000003520.
    >> Share

  118. DE CASTRO N, Chazallon C, Brites C, Messou E, et al
    Virologic response to antiretroviral therapy in people with HIV and tuberculosis in high-TB burden countries.
    AIDS. 2023 Feb 17. doi: 10.1097/QAD.0000000000003521.
    >> Share

  119. ZINO L, Jacobs TG, Nieuwenstein T, Grintjes K, et al
    Model-informed intermittent tenofovir disoproxil fumarate and emtricitabine dosing for HIV pre-exposure prophylaxis in subjects with renal impairment: a case report.
    AIDS. 2023;37:363-365.
    >> Share

  120. HANTTU AM, Pekkala S, Satokari R, Hartikainen AK, et al
    Gut microbiota alterations after switching from a protease inhibitor or efavirenz to raltegravir in a randomized, controlled study.
    AIDS. 2023;37:323-332.
    >> Share

    January 2023
  121. BOWMAN C, Ambrose A, Kanitkar T, Flores K, et al
    Real world use of dolutegravir two drug regimens.
    AIDS. 2023 Jan 16. doi: 10.1097/QAD.0000000000003480.
    >> Share

    December 2022
  122. HORNER MJ, Hazra R, Barnholtz-Sloan JS, Shiels MS, et al
    Cancer risk among HIV-exposed uninfected children in the United States.
    AIDS. 2022 Dec 23. doi: 10.1097/QAD.0000000000003458.
    >> Share

  123. PERNA A, Carleo MA, Mascolo S, Guida A, et al
    Adipocyte differentiation of 3T3-L1 cells under TAF, TDF and INSTIs selective challenge: an in vitro model.
    AIDS. 2022 Dec 13. doi: 10.1097/QAD.0000000000003455.
    >> Share

  124. BARCHI V, Rindi LV, Iannazzo R, Massa B, et al
    Doravirine/lamivudine/tenofovir disoproxil fumarate-induced hypertriglyceridemia in a newly diagnosed AIDS patient.
    AIDS. 2022;36:2231-2233.
    >> Share

  125. DEL AMO J, Polo R, Moreno S, Martinez E, et al
    Tenofovir disoproxil fumarate/emtricitabine and severity of coronavirus disease 2019 in people with HIV infection.
    AIDS. 2022;36:2171-2179.
    >> Share

    November 2022
  126. VAN ZYL G, Jennings L, Kellermann T, Nkantsu Z, et al
    Urine tenofovir-monitoring predicts HIV viremia in patients treated with high genetic-barrier regimens.
    AIDS. 2022;36:2057-2062.
    >> Share

  127. MILNE RS, Beck IA, Levine M, So I, et al
    Low-frequency pre-treatment HIV drug resistance: effects on 2-year outcome of first-line efavirenz-based antiretroviral therapy.
    AIDS. 2022;36:1949-1958.
    >> Share

  128. RATHORE U
    Mitochondrial dysfunction in people with HIV receiving contemporary antiretroviral therapy.
    AIDS. 2022;36:2063-2064.
    >> Share

  129. LUMU I, Musaazi J, Castelnuovo B
    Durability of switched therapy after failure of WHO-recommended antiretroviral therapy regimens in a resource-limited setting.
    AIDS. 2022;36:1791-1800.
    >> Share

    October 2022
  130. DICKSON S, Gabriel N, Hernandez I
    Estimated changes in price discounts for tenofovir-inclusive HIV treatments following introduction of tenofovir alafenamide.
    AIDS. 2022 Oct 7. pii: 00002030-990000000-00122.
    >> Share

    September 2022
  131. LUBEGA J, Kim TO, Airewele G, Grimes A, et al
    Risk factors and prognostic significance of platelet count abnormalities in children with HIV infection on anti-retrovirus therapy.
    AIDS. 2022 Sep 20. pii: 00002030-990000000-00116.
    >> Share

  132. YOUNGPAIROJ AS, Vanderford TH, Reed MS, Granade TC, et al
    A monoclonal antibody for the detection of the antiretroviral drug emtricitabine.
    AIDS. 2022 Sep 16. pii: 00002030-990000000-00092.
    >> Share

  133. LONDERO A, Fusi M, Cinausero M, Tascini C, et al
    Effects of the androgen receptor inhibitor enzalutamide on the pharmacokinetics of dolutegravir and tenofovir: a case report.
    AIDS. 2022;36:1603-1605.
    >> Share

  134. LUBEGA J, Grimes A, Airewele G, Bulsara S, et al
    Risk factors and prognostic significance of anemia in children with hiv infection on anti-retroviral therap.
    AIDS. 2022 Sep 1. pii: 00002030-990000000-00106.
    >> Share

    August 2022
  135. JASCHINSKI N, Greenberg L, Neesgaard B, Miro JM, et al
    Recent abacavir use and incident cardiovascular disease in contemporary treated people living with HIV.
    AIDS. 2022 Aug 24. pii: 00002030-990000000-00102.
    >> Share

  136. AJAYKUMAR A, Caloren LC, Povshedna T, Hsieh AYY, et al
    Dolutegravir-containing HIV therapy reversibly alters mitochondrial health and morphology in cultured human fibroblasts and PBMC.
    AIDS. 2022 Aug 24. pii: 00002030-990000000-00104.
    >> Share

  137. THEERASUWIPAKORN N, Rungpradubvong V, Chattranukulchai P, Siwamogsatham S, et al
    Higher prevalence of QTc interval prolongation among virologically suppressed older people living with HIV.
    AIDS. 2022 Aug 16. pii: 00002030-990000000-00090.
    >> Share

  138. LAKE JE, Wang R, Barrett BW, Bowman E, et al
    Trans women have worse cardiovascular biomarker profiles than cisgender men independent of hormone use and HIV serostatus.
    AIDS. 2022 Aug 11. pii: 00002030-990000000-00081.
    >> Share

  139. STAPLETON JT, Bedimo RJ, Guaraldi G
    Switch back from TAF to TDF or rather switch forward from metabolic toxicities of drugs to metabolic health of people living with HIV.
    AIDS. 2022;36:1457-1459.
    >> Share

    July 2022
  140. LI G, Park LS, Lodi S, Logan RW, et al
    Tenofovir disoproxil fumarate and COVID-19 outcomes in men with HIV.
    AIDS. 2022 Jul 15. pii: 00002030-990000000-00063.
    >> Share

  141. POLI G, Stapleton JT
    Sex matters... cytokines and disease progression in men and women receiving combination antiretroviral therapy.
    AIDS. 2022;36:1307-1309.
    >> Share

  142. MICAN R, Grela AG, Cadinanos J, de Miguel R, et al
    Impact of Pre-Existing Nrti Resistance on the Effectiveness of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Treatment Experience Patients: Real-World Data.
    AIDS. 2022 Jul 8. pii: 00002030-990000000-00052.
    >> Share

    June 2022
  143. KAUPPINEN KJ, Aho I, Sutinen J
    Switching from tenofovir alafenamide to tenofovir disoproxil fumarate improves lipid profile and protects from weight gain.
    AIDS. 2022 Jun 22. pii: 00002030-990000000-00035.
    >> Share

  144. HUNT M, Phillips R, Hardy Y, Owusu DO, et al
    Renal mitochondrial toxicity: effects of thymidine analogues and tenofovir disoproxil fumarate in African people with HIV.
    AIDS. 2022;36:1049-1051.
    >> Share

  145. POST FA, Sinxadi P
    Tenofovir disoproxil and renal mitochondrial toxicity: more studies in Africans are needed.
    AIDS. 2022;36:1047-1048.
    >> Share

  146. JIANG W, Ronen K, Osborn L, Drake AL, et al
    Predictors of adverse pregnancy outcomes among Kenyan women with HIV on antiretroviral treatment in pregnancy.
    AIDS. 2022;36:1007-1019.
    >> Share

    May 2022
  147. PORTWOOD C, Sexton H, Kumarendran M, Brandon Z, et al
    Adverse perinatal outcomes associated with HAART and monotherapy: systematic review and meta-analysis.
    AIDS. 2022 May 24. pii: 00002030-990000000-00018.
    >> Share

  148. GIOVENCO D, Pettifor A, Powers KA, Hightow-Weidman L, et al
    Intimate partner violence and oral HIV pre-exposure prophylaxis adherence among young African women.
    AIDS. 2022 May 17. pii: 00002030-990000000-00015.
    >> Share

    April 2022
  149. SAX PE, Andreatta K, Molina JM, Daar ES, et al
    High Efficacy of Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide in People with Suppressed HIV and Preexisting M184 V/I.
    AIDS. 2022 Apr 23. pii: 00002030-990000000-00011.
    >> Share

    March 2022
  150. LEPIK KJ, Wang L, Harris M, Mclinden T, et al
    Evolving patterns of antiretroviral drug interactions in people living with HIV in British Columbia, Canada.
    AIDS. 2022 Mar 11. pii: 00002030-990000000-00005.
    >> Share

    January 2022
  151. LI B, Zhang L, Liu Y, Xiao J, et al
    A novel prediction model to evaluate the probability of CD4/CD8 ratio restoration in HIV-infected individuals.
    AIDS. 2022 Jan 14. pii: 00002030-900000000-96239.
    >> Share

  152. NOVAK RM, Armon C, Battalora L, Buchacz K, et al
    Aging, trends in CD4/CD8 ratio and clinical outcomes with persistent HIV suppression in the HIV outpatient study (HOPS).
    AIDS. 2022 Jan 10. pii: 00002030-900000000-96237.
    >> Share

    December 2021
  153. PAPOT E, Kaplan R, Vitoria M, Polizzotto MN, et al
    Optimizing switching strategies to simplify antiretroviral therapy: the future of second-line from a public health perspective.
    AIDS. 2021;35.
    >> Share

  154. DALLA-POZZA P, Hentzien M, Allavena C, Maindreville AD, et al
    Progressive multifocal leukoencephalopathy in patients with immuno-virological control and at least 6 months of combination antiretroviral therapy.
    AIDS. 2021 Dec 6. pii: 00002030-900000000-96259.
    >> Share

    September 2021
  155. QU Y, Weinstein A, Wang Z, Cheng Y, et al
    Legacy effect on neuropsychological function in HIV-infected men on combination antiretroviral therapy.
    AIDS. 2021 Sep 13. pii: 00002030-900000000-96316.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016